
|Videos|May 1, 2013
Patrick Gleason of Prime Therapeutics on Pharmacogenomic Testing
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
3
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
4
Workforce Preparation for Fall Immunization Season Starts Now
5






































































































